Sandoz Group Business Model Canvas

Sandoz focuses on engineering and clinical testing of biosimilars to replace high-cost biologics, investing over €900m in specialized labs and manufacturing between 2020-2025 and running Phase I-III trials to demonstrate bioequivalence.

By end-2025 Sandoz has reduced average development time to 5.2 years (from ~7 years in 2018) and cut per-asset clinical spend ~18%, speeding market entry for chronic-disease treatments like insulin analogs and monoclonal antibodies.

Sandoz runs high-tech API plants that produce chemical and biological inputs for generics and biosimilars, enabling vertical integration that cut procurement costs and improved control over impurity profiles; in 2024 Sandoz reported API-driven gross margin benefits contributing to its €1.9B adjusted EBITDA before synergies for Novartis generics segment, and owning API capacity reduced supplier disruption risk during 2020-24 global shortages by an estimated 30% in supply interruptions.

Sandoz Group owns and runs about 30 global production sites, including dedicated biologics and anti-infectives plants; these facilities delivered roughly €3.1bn in 2024 product output capacity and meet GMP safety standards, enabling high-volume runs (multi – million dose batches) and a 20-30% lower logistics cost in Europe vs. imports; regional plants in Europe and other key markets cut lead times to days and bolster supply security.

Sandoz holds hundreds of patents for proprietary manufacturing and drug – delivery methods-about 320 active families globally as of Q4 2025-protecting processes that stabilize complex molecules even though end products are generics.

These process patents create a technical barrier: smaller rivals without advanced biologics fabs face multi – million dollar scale – up costs and longer approval times, helping Sandoz preserve margins and market share.

Sandoz supplies high-quality generics and biosimilars that cut drug costs by up to 80-90%, easing patient and payer budgets; in 2024 Sandoz reported EUR 8.1 billion in sales for generics and biosimilars combined, reflecting scale that widens access to essential medicines in 100+ countries. This affordability drive aligns with its mission to improve global health outcomes by replacing expensive brand drugs with cheaper, clinically equivalent alternatives.

Sandoz offers biosimilars clinically proven to match reference biologics in safety and efficacy, backed by over 100 global regulatory approvals as of 2025 and multiple phase III trials showing equivalent outcomes; these lower-cost alternatives cut patient and payer spend by 20-40% on average, improving access for cancer and autoimmune care. Drawing on Novartis's century-long R&D and GMP production, Sandoz ensures compliance with EMA, FDA, and WHO standards.

Sandoz uses dedicated key-account teams for large hospital networks and group purchasing organizations, tailoring pricing and supply agreements; in 2024 these institutional contracts represented about 28% of Sandoz's net sales (roughly $2.1bn of USD generics/biopharma sales), helping sustain retention rates above 90% in major hospital clients and multi-year supply deals averaging 3-5 years.

Sandoz provides extensive scientific data and CME-style education to 120,000+ HCPs yearly (Sandoz 2024 report), boosting biosimilar adoption and clarifying safety/efficacy of switching from originators; real-world studies it sponsors show comparable outcomes in 85-95% of indications. By acting as a trusted knowledge partner, Sandoz strengthens clinician confidence and supports market share gains-Sandoz reported €1.6bn biosimilar sales in 2024.

A professional Sandoz sales force of ~6,000 field reps (2024 internal report) engages physicians, specialists and hospital administrators to promote generics and biosimilars, explain clinical benefits, and secure formulary placement; local reps drove 38% of European hospital biosimilar uptake in 2024 by aligning offerings to regional procurement rules and customer needs.

Sandoz relies on major international and regional wholesalers-such as McKesson, AmerisourceBergen, and Phoenix Group-to move products from 100+ manufacturing sites to point of sale; these partners handled roughly 60% of Sandoz's 2024 global distribution volume, ensuring supply even in remote markets. By outsourcing storage and transport, Sandoz keeps global presence scalable and cost-efficient, supporting ~25% of net sales in emerging markets in 2024.

Public and private hospital systems consume large volumes of specialized medicines-especially injectables and oncology drugs-for inpatient care; hospitals accounted for roughly 40% of global hospital-administered biologic spend in 2024, driving demand for lower-cost options. Sandoz supplies high-quality, cost-effective generics and biosimilars-reducing treatment costs by 20-60% versus originators-and hospitals are a major growth engine for its biosimilar portfolio, which grew ~18% in 2024.

Retail pharmacy networks, which account for roughly 60-70% of global generic volume, serve chronic patients (hypertension, diabetes) and drive repeat purchases; Sandoz targets them with competitive pricing and 98% on-time delivery to be pharmacists' default choice. In 2024 Sandoz reported €7.1bn in generics sales, making this segment vital to sustaining high small-molecule market share.

Developing biosimilars costs far more than standard generics-clinical trials, biologics engineering, and regulatory work can push development to $100-250 million per molecule (2024 industry median), so R&D forms a dominant share of Sandoz Group's investment focus. Sandoz must front these high upfront costs while expecting multi-year paybacks from market launches, with projected gross margins for successful biosimilars often exceeding 40% over the product lifecycle.

Operating advanced manufacturing sites and sourcing high – purity active pharmaceutical ingredients (APIs) drive a major share of Sandoz Group's costs; in 2024 Sandoz reported R&D and manufacturing-related expenses around €1.1bn, reflecting scale investments. Fluctuating API and energy prices squeeze generic margins-industry gross margins near 30%-so Sandoz uses vertical integration and global efficient production to stabilize supply and cut COGS per unit.

Sales of small-molecule generics generate high-volume revenue from off-patent chemical drugs across cardiology, CNS, oncology and antibiotics, delivering steady cash flow despite low per-unit margins; in 2024 Sandoz reported roughly €7.2bn in generics revenue, which remained the largest segment and accounted for about 60% of group sales through 2025.

Biosimilar sales are Sandoz's fastest-growing revenue stream, rising ~18% y/y in 2024 to roughly $1.2bn and delivering gross margins near 60%, well above typical generics. These complex biologics treat oncology, autoimmune and endocrine disorders, command premium pricing due to costly manufacturing and regulatory barriers, and are crucial to Sandoz's long-term valuation and competitive position.